VERISANTE TECH (V3T.F)
-Frankfurt 0.31 
0.07(19.26%) May 13
| Prev Close: | 0.31 |
|---|
| Open: | N/A |
|---|
| Bid: | 0.28 |
|---|
| Ask: | 0.30 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.30 - 0.30 |
|---|
| 52wk Range: | 0.28 - 0.49 |
|---|
| Volume: | 20,000 |
|---|
| Avg Vol (3m): | 352 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- Verisante Aura is Named a 2013 Bronze Edison Award WinnerMarketwired(Fri, Apr 26)
- Verisante Announces Official Launch of Aura in GermanyMarketwired(Wed, Mar 20)
- Verisante Technology, Inc. Announces Exclusive Distribution Agreement with Pacifica Handels AG for SwitzerlandMarketwired(Tue, Feb 19)
- Verisante Named Edison Awards FinalistMarketwired(Wed, Feb 13)
- Verisante Technology, Inc. Retains Hamza Thindal Capital Corp. for Investor RelationsMarketwired(Fri, Feb 8)
- Verisante Wins Prism Award at SPIE Photonics West Gala; Prestigious Honour Comes as the Company Begins to Place the Innovative Skin Cancer Detector at Clinics Across Canada and EuropeMarketwired(Thu, Feb 7)
- Verisante Technology, Inc. Announces First Sales of Aura, a Revolutionary Medical Device for the Detection of Skin CancerMarketwired(Wed, Jan 30)
- Verisante Technology, Inc. Announces First Sales of Aura, a Revolutionary Medical Device for the Detection of Skin CancerMarketwired(Wed, Jan 30)
- Verisante Technology, Inc. Retains Crescendo Communications for Investor RelationsMarketwired(Tue, Jan 29)
- Verisante Technology, Inc. Retains Crescendo Communications for Investor RelationsMarketwired(Tue, Jan 29)
- Verisante Technology, Inc. Announces Expansion of Exclusive Distribution Agreement with bo pharma BV into Nordic CountriesMarketwired(Thu, Jan 17)
- Verisante Technology, Inc. Announces Exclusive Distribution Agreement With Laserwelt Berlin for Germany, Austria and LiechtensteinMarketwired(Thu, Jan 10)
- Verisante Technology, Inc. Announces Study Results for Lung CancerMarketwired(Wed, Nov 28)
- Verisante Aura Named Finalist for 2013 SPIE Prism AwardMarketwired(Tue, Nov 20)
- Verisante Technology, Inc. Issues Operational Update; Beta Units in Clinics Across Canada, Distribution Sales Force Being TrainedMarketwired(Thu, Nov 8)
Reports
- No Reports available for V3T.F at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forV3T.F.